Pfizer Expands Oncology Pipeline With New PF-08634404 Combo Trial in Advanced Lung Cancer

Pfizer Inc (PFE) announced an update on their ongoing clinical study.Claim 55% Off TipRanksUnlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter Pfizer Inc. (PFE) is advancing a new early-stage cancer study, formally titled “An Interventional Open-Label Phase 1B/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in Combination With Different Anticancer Agents in Participants With Advanced Solid Tumors.” The trial aims to see how this new drug works with other treatments in advanced non-small cell lung cancer and other solid tumors. The study tests PF-08634404, also known as SSGJ-707, given by IV infusion. It is used in combination with other anticancer drugs to see if these pairings can safely control hard-to-treat cancers that no longer respond to standard care. In Part A, PF-08634404 is combined with sigvotatug vedotin, a targeted cancer drug also delivered by IV. In Part B, PF-08634404 is paired with another anticancer agent, called Combination Agent 1, to explore different treatment options that might extend use across cancer types. This is an interventional Phase 1B/2 study with a non-randomized, step-by-step (sequential) design. There is no blinding, so doctors and patients know which drugs are given, and the main goal is treatment, focusing first on safety and early signs that tumors may shrink or stop growing. The study is listed as recruiting, with first submission recorded on November 7, 2025, signaling that sites are in the process of opening or enrolling. The primary completion and final completion dates are not yet posted, while the last update on June 3, 2026, confirms the protocol and status have been recently refreshed. For investors, this update supports Pfizer’s push in oncology beyond its current portfolio and COVID-era revenues. While Phase 1B/2 results are years away and high risk, any positive signals could strengthen PFE’s long-term growth story and help it compete with Merck, Bristol Myers, and other major cancer players. The broader lung cancer market is crowded, but a successful new combination could carve out a niche in patients who have exhausted current options. Near term, sentiment impact is modest, yet continued pipeline activity may support valuation resilience and attract investors looking for oncology-driven upside in large-cap pharma. The study remains active and updated, with further details available on the ClinicalTrials.gov portal under identifier NCT07227298. To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.